Abstract
In a landmark multi-center, phase III, randomized controlled trial — PARADIGM-HF, that investigated long-term effects and safety of novel class of agents — angiotensin receptor antagonist/neprilisin inhibitor (ARNI) — LCZ696 (sacubitril/ /valsartan) in comparison with enalapril, clear clinical benefit was shown in patients with heart failure with reduced ejection fraction (HFrEF) who were subjected to sacubitril/valsartan. Sacubitril/valsartan ( Entresto TM ) has been avai- lable in Poland for the last two years. The present document is a practical guide for all those physicians who would like to initiate this new therapy for the first time and also for those have gathered so far some experience with Entresto TM .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
